分组1 - Integral Ad Science (IAS) reported quarterly earnings of $0.07 per share, missing the Zacks Consensus Estimate of $0.09 per share, and down from $0.10 per share a year ago, representing an earnings surprise of -22.22% [1] - The company posted revenues of $154.36 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 3.32%, and up from $133.53 million year-over-year [2] - IAS has surpassed consensus revenue estimates four times over the last four quarters, indicating a positive trend in revenue performance [2] 分组2 - The stock has underperformed the market, losing about 2.1% since the beginning of the year compared to the S&P 500's gain of 16.5% [3] - The current consensus EPS estimate for the coming quarter is $0.13 on revenues of $169.58 million, and for the current fiscal year, it is $0.35 on revenues of $602.2 million [7] - The Advertising and Marketing industry, to which IAS belongs, is currently in the bottom 42% of the Zacks industry rankings, which may impact stock performance [8]

分组1 - Neuronetics reported a quarterly loss of $0.13 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.11, but an improvement from a loss of $0.29 per share a year ago, indicating an earnings surprise of -18.18% [1] - The company posted revenues of $37.3 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 2.21%, but showing significant growth from $18.53 million in the same quarter last year [2] - Neuronetics shares have increased approximately 72.1% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] 分组2 - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The trend of estimate revisions for Neuronetics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market [6] - The current consensus EPS estimate for the upcoming quarter is -$0.09 on revenues of $42.37 million, and for the current fiscal year, it is -$0.56 on revenues of $150.79 million [7] 分组3 - The Medical - Instruments industry, to which Neuronetics belongs, is currently ranked in the top 38% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - Verastem reported a quarterly loss of $1.35 per share, significantly worse than the Zacks Consensus Estimate of a loss of $0.51, marking an earnings surprise of -164.71% [1] - The company achieved revenues of $11.24 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 82.80%, compared to zero revenues a year ago [2] Financial Performance - The loss per share increased from $0.60 a year ago to $1.35 this quarter, indicating a worsening financial situation [1] - Over the last four quarters, Verastem has only surpassed consensus EPS estimates once [2] Stock Performance - Verastem shares have increased approximately 91.5% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] - The stock currently holds a Zacks Rank 2 (Buy), suggesting it is expected to outperform the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.42 on revenues of $22.07 million, and for the current fiscal year, it is -$2.44 on revenues of $18.75 million [7] - The outlook for the industry, specifically the Medical - Biomedical and Genetics sector, is favorable, ranking in the top 39% of over 250 Zacks industries [8]

Core Insights - Harmony Biosciences reported quarterly earnings of $0.87 per share, missing the Zacks Consensus Estimate of $0.92 per share, but showing an increase from $0.79 per share a year ago, resulting in an earnings surprise of -5.43% [1] - The company posted revenues of $239.46 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 4.59% and up from $186.04 million year-over-year [2] - Harmony Biosciences shares have declined approximately 14.8% year-to-date, contrasting with the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $1.05 on revenues of $239.18 million, and for the current fiscal year, it is $3.23 on revenues of $864.24 million [7] - The estimate revisions trend for Harmony Biosciences was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Harmony Biosciences belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Core Insights - Amicus Therapeutics reported quarterly earnings of $0.17 per share, exceeding the Zacks Consensus Estimate of $0.12 per share, and showing an increase from $0.10 per share a year ago, resulting in an earnings surprise of +41.67% [1] - The company achieved revenues of $169.06 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.61% and up from $141.52 million year-over-year [2] - The stock has underperformed the market, losing about 5.9% year-to-date compared to the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.16 on revenues of $179.38 million, and for the current fiscal year, it is $0.31 on revenues of $624.06 million [7] - The estimate revisions trend for Amicus Therapeutics was favorable ahead of the earnings release, resulting in a Zacks Rank 2 (Buy) for the stock, indicating expected outperformance in the near future [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Amicus Therapeutics belongs, is currently ranked in the top 39% of over 250 Zacks industries, suggesting a favorable outlook for stocks within this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Insights - Xometry reported quarterly earnings of $0.11 per share, matching the Zacks Consensus Estimate, and showing an increase from $0.02 per share a year ago [1] - The company achieved revenues of $180.72 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 7.42% and up from $141.7 million year-over-year [2] - Xometry's stock has increased approximately 13.9% year-to-date, compared to a 16.5% gain in the S&P 500 [3] Earnings Performance - The company has surpassed consensus EPS estimates three out of the last four quarters, with a notable surprise of +80% in the previous quarter [1] - The current consensus EPS estimate for the upcoming quarter is $0.13, with expected revenues of $175.59 million, and for the current fiscal year, the estimate is $0.35 on revenues of $657.33 million [7] Market Outlook - The sustainability of Xometry's stock price movement will largely depend on management's commentary during the earnings call [3] - The Zacks Rank for Xometry is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] - The Manufacturing - General Industrial industry, to which Xometry belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, which may impact stock performance [8]

Core Insights - Anywhere Real Estate reported break-even quarterly earnings per share, missing the Zacks Consensus Estimate of $0.18, compared to earnings of $0.05 per share a year ago, resulting in an earnings surprise of -100.00% [1] - The company posted revenues of $1.63 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 4.20%, and showing an increase from $1.54 billion year-over-year [2] - The stock has increased approximately 208.8% since the beginning of the year, significantly outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.13 on revenues of $1.38 billion, and for the current fiscal year, it is -$0.20 on revenues of $5.83 billion [7] - The estimate revisions trend for Anywhere Real Estate was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Real Estate - Operations industry is currently in the top 27% of over 250 Zacks industries, suggesting a favorable outlook as the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8] - Sunrise Realty Trust, Inc., another company in the same industry, is expected to report quarterly earnings of $0.31 per share, reflecting a year-over-year change of +24%, with revenues anticipated to be $6.2 million, up 95% from the previous year [9][10]

Core Insights - CDW reported quarterly earnings of $2.71 per share, exceeding the Zacks Consensus Estimate of $2.62 per share, and showing an increase from $2.63 per share a year ago, resulting in an earnings surprise of +3.44% [1] - The company achieved revenues of $5.74 billion for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.86% and up from $5.52 billion year-over-year [2] - CDW has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance [2] Earnings and Revenue Performance - The earnings surprise for the previous quarter was +4.42%, with actual earnings of $2.60 per share compared to an expected $2.49 per share [1] - The current consensus EPS estimate for the upcoming quarter is $2.51, with projected revenues of $5.16 billion, while the estimate for the current fiscal year is $9.86 on $22.03 billion in revenues [7] Market Position and Outlook - CDW shares have underperformed the market, losing about 11% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The company's Zacks Rank is currently 3 (Hold), suggesting that shares are expected to perform in line with the market in the near future [6] - The Computers - IT Services industry, to which CDW belongs, is currently in the top 28% of Zacks industries, indicating a favorable industry outlook [8]

Core Insights - Kymera Therapeutics reported a quarterly loss of $0.9 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.71, marking a surprise of -26.76% [1] - The company's revenues for the quarter ended September 2025 were $2.76 million, missing the Zacks Consensus Estimate by 89.6%, and down from $3.74 million a year ago [2] - The stock has increased approximately 48.5% since the beginning of the year, outperforming the S&P 500's gain of 16.5% [3] Financial Performance - Over the last four quarters, Kymera Therapeutics has surpassed consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is -$0.85 on revenues of $20.64 million, and for the current fiscal year, it is -$3.28 on revenues of $80.83 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Kymera Therapeutics belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Kymera's stock performance [5][6]

分组1 - Zoetis reported quarterly earnings of $1.7 per share, exceeding the Zacks Consensus Estimate of $1.62 per share, and showing an increase from $1.58 per share a year ago, resulting in an earnings surprise of +4.94% [1] - The company posted revenues of $2.4 billion for the quarter ended September 2025, slightly missing the Zacks Consensus Estimate by 0.35%, but showing a year-over-year increase from $2.39 billion [2] - Over the last four quarters, Zoetis has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] 分组2 - The stock has underperformed the market, losing about 11.4% since the beginning of the year, while the S&P 500 has gained 16.5% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for future stock performance [4] - The current consensus EPS estimate for the coming quarter is $1.48 on revenues of $2.42 billion, and for the current fiscal year, it is $6.35 on revenues of $9.5 billion [7] 分组3 - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the top 36% of over 250 Zacks industries, suggesting that stocks in the top 50% outperform those in the bottom 50% by more than 2 to 1 [8] - The estimate revisions trend for Zoetis was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6]